ADC Summit | Exclusive Interview Photobiotics

LONDON, UNITED KINGDOM, April 17, 2014 /EINPresswire.com/ -- In the run up to SMi’s 3rd annual ADC Summit, SMi Group Ltd would like to thank conference speaker, Dr Mahendra Deonarain, for taking time out to give us his views on the conference, challenges facing the industry and the future of ADC’s.

Dr Mahendra Deonarain, Chief Scientific Officer from Photobiotics will be presenting at this year summit alongside a panel of ADC industry leaders including Ablynx, Polytherics, MedImmune, Genetech, Spirogen, Pfizer plus many more. His presentation entitled: Antibody Fragment ADC’s, will include updates on the use of single chain Fvs and payloads.

“The SMI ADC summit is a great place to showcase our technologies and interact with future potential partners and collaborators to help take your business forward”

When questioned on the biggest challenges and importance of antibody fragment ADC’s, Dr Deonarain stated,

“Antibody fragment ADCs have never been seriously considered as they clear too quickly to have enough potency. But with enough payload attached and a modified half-life they could compete with whole antibody ADCs whilst having less if the side effects associated with the Fc part of an antibody…The biggest challenge for us remains the issue of bioanalytics. With such a complicated therapeutic, we need to know exactly how well our payloads have conjugated and what the effect is on the antibody carrier.”

When asked to give a reason why key players in the ADC industry should attend the summit, he commented:

“The ADC summit will have representatives from all the innovators in the field and allow you to benchmark your own technology as well as bounce ideas off people in an informal setting. London is a world-class hub for biotech innovation, especially in bioconjugation technologies and ADCs. “
The full interview can be read in the event download centre at www.adcsummit.com


ADC SUMMIT 2014
19TH – 20TH MAY 2014
www.adcsummit.com
Holiday Inn Kensington Forum, London UK
Sponsored by PolyTherics, Synaffix and Viventia Bio Inc

About SMi Group

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries.
We pride ourselves on having access to the worlds most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. We hold events in over 30 major cities throughout the world including London, Paris and Singapore and to date have welcomed over 200,000 participants from 80 countries. More information can be found at www.smi-online.co.uk

About PhotoBiotics

PhotoBiotics Ltd is a multidisciplinary company spun out from Imperial College London to explore ways of targeting drugs directly to tumours, thus enhancing the efficacy of cancer treatment while also reducing fragments. Counter-intuitively, OptiLink allows far higher drug loadings on antibody fragments than normally achieved with whole monoclonal antibodies. The PhotoBiotics' R&D team has already succeeded data in various orthotopic and xenograft models, and has a product ready to enter preclinical toxicology/clinical development. The Company is now exemplifying how OptiLink has utility across a wide range of other ADC applications, including the targeted delivery of conventional cytotoxic drugs and MRI (Magnetic Resonance Imaging) contrast agents.

Teri Arri
SMi Group Ltd
+44 (0)20 7827 6162
email us here